التفاصيل البيبلوغرافية
| العنوان: |
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. |
| المؤلفون: |
Roberto, Michela, Romiti, Adriana, Botticelli, Andrea, Mazzuca, Federica, Paris, Ida, Falcone, Rosa, Bassanelli, Maria, Di Pietro, Francesca, Onesti, Concetta, Anselmi, Elisabetta, Macrini, Serena, Marchetti, Paolo, Lionetto, Luana, Gentile, Giovanna, Simmaco, Maurizio |
| المصدر: |
European Journal of Clinical Pharmacology; Feb2017, Vol. 73 Issue 2, p157-164, 8p |
| مصطلحات موضوعية: |
ANTIMETABOLITES, BIOMARKERS, CONFIDENCE intervals, DRUG side effects, FLUOROURACIL, GENETIC polymorphisms, HEALTH outcome assessment, PHARMACOGENOMICS, POLYMERASE chain reaction, TOXICITY testing, GASTROINTESTINAL tumors, PREDICTIVE tests, RETROSPECTIVE studies, DATA analysis software, INDIVIDUALIZED medicine, DESCRIPTIVE statistics, ODDS ratio |
| مستخلص: |
Background: On account of the lack of predictive biomarkers of toxicity, we investigated whether polymorphisms of genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with outcomes of adjuvant capecitabine in patients with early stage gastrointestinal cancers. Methods: Genotyping of DPYD GIVS14A, MTHFR C677T and A1298C SNPs were performed by pyro-sequencing technology. PCR analysis was used for genotyping TYMS-TSER. We also evaluated the 5-FU degradation rate, which determines the amount of drug consumed by PBMC in a time unit. Association of these variables with clinical outcome was evaluated using multivariate logistic regression analysis. Results: One hundred forty-two patients with early stage colon (39%), rectal (28%), stomach (20%) and pancreatic (13%) cancer, treated with adjuvant capecitabine, were included in this retrospective analysis. Seventy and 20% of the patients suffered from at least one G1-4 and G3-4 adverse events, respectively. According to the 5-FU degradation rate, three and 13 patients were assigned as poor (<0.86 ng/mL/10 cells/min) and ultra-rapid (>2.1 ng/mL/10 cells/min) metabolizers, respectively. At a multivariate logistic regression analysis, an altered 5-FU degradation rate (values <0.86 or >2.10 ng/mL/10 cells/min) was associated with grade 3-4 adverse events (OR = 2.09, 95% CI: 1.14-3.82, P = 0.01). No correlation was reported between toxicity and gene polymorphisms except for hand-foot syndrome that was more frequent in the MTHFR 1298CC homozygous variant genotype (OR = 2.03, 95% CI 1.04-3.96, P = 0.03). Conclusions: 5-FU degradation rate may be regarded as possible predictive biomarker of capecitabine toxicity in early stage gastrointestinal cancer. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Clinical Pharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
